文献速递前列腺癌

既往PARP抑制剂暴露与携带DNA同源重组修复基因突变的去势抵抗性前列腺癌男性接受177Lu-PSMA-617治疗后的临床结局的相关性

Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes.
PubMed 文献 · Eur Urol Oncol · 2025-02-07

这项回顾性研究纳入100例携带PARP抑制剂适应同源重组修复(HRR)基因改变并接受177Lu-PSMA-617(LuPSMA)治疗的患者,比较既往未接受(PARPi-N)与接受过(PARPi-T)PARP抑制剂者的结局。两组PSA50缓解率相似,但PARPi-N组PSA无进展生存期更长(9.1 vs 4.8个月;p=0.037);在BRCA2改变患者中,PARPi-N组PSA50缓解率(89% vs 35%;p=0.009)和PSA无进展生存期(14 vs 2.9个月;p=0.026)更优。作者认为PARP抑制剂暴露与LuPSMA结局较差相关,尤其BRCA2改变者,并提示潜在交叉耐药,需前瞻性研究评估最佳序贯。

要点

  • PARPi-N组与PARPi-T组LuPSMA后PSA50缓解率相似,但PARPi-N组PSA无进展生存期更长(9.1 vs 4.8个月;p=0.037)。
  • BRCA2改变患者中,PARPi-N组PSA50缓解率89% vs PARPi-T组35%(p=0.009),PSA无进展生存期14 vs 2.9个月(p=0.026)。
  • ATM改变患者中,PARP抑制剂暴露未影响LuPSMA结局。

核心结论

  • PARP抑制剂暴露与LuPSMA结局较差相关,尤其在BRCA2改变患者中;作者认为这提示潜在交叉耐药,并强调需前瞻性研究评估这些药物的最佳序贯。

研究设计与样本

  • 回顾性研究,纳入100例携带PARP抑制剂适应HRR基因改变并接受LuPSMA治疗的患者。
  • 比较既往未接受PARP抑制剂(PARPi-N,n=47)与接受过(PARPi-T,n=53)者的LuPSMA临床结局。
  • 对最常见HRR改变(BRCA2和ATM)进行亚组分析。

主要发现

  • LuPSMA后PSA50缓解率在PARPi-N组(n=47)与PARPi-T组(n=53)相似,但PARPi-N组PSA无进展生存期更长(9.1 vs 4.8个月;p=0.037)。
  • BRCA2改变患者中,PARPi-N组较PARPi-T组PSA50缓解率更高(89% vs 35%;p=0.009),PSA无进展生存期更长(14 vs 2.9个月;p=0.026),总生存期(19 vs 5.3个月;p=0.10)。
  • ATM改变患者中,PARP抑制剂暴露未影响LuPSMA结局。

局限性

  • 局限性包括回顾性设计以及两组既往治疗线数存在差异。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: The prostate-specific membrane antigen (PSMA) radioligand 177Lu-PSMA-617 (LuPSMA) is approved for treatment of metastatic castration-resistant prostate cancer (mCRPC). PARP inhibitors (PARPi) are approved for patients with mCRPC and mutations in homologous recombination repair (HRR) pathway genes. Both modalities induce DNA damage and therefore may share mechanisms of resistance. We investigated whether PARPi exposure would reduce the subsequent efficacy of LuPSMA. METHODS: This retrospective study included 100 patients with a PARPi-qualifying HRR alteration treated with LuPSMA. Clinical outcomes on LuPSMA, including PSA50 response, PSA progression-free survival (PFS), and overall survival (OS), were compared between those who had not previously received PARPi (PARPi-N) and those who had (PARPi-T). Subgroup analyses were performed for the most frequent HRR alterations (BRCA2 and ATM). KEY FINDINGS AND LIMITATIONS: PSA50 responses on LuPSMA were similar between PARPi-N (n = 47) and PARPi-T (n = 53), although PSA PFS was longer in the PARPi-N group (9.1 vs 4.8 mo; p = 0.037). Among patients with BRCA2 alterations, the PARPi-N group had a better PSA50 response rate (89% vs 35%; p = 0.009), PSA PFS (14 vs 2.9 mo; p = 0.026), and OS (19 vs 5.3 mo; p = 0.10). PARPi exposure did not influence LuPSMA outcomes among patients with ATM alterations. Limitations include the retrospective design and differences in prior lines of therapy between the groups. CONCLUSIONS AND CLINICAL IMPLICATIONS: PARPi exposure is associated with inferior LuPSMA outcomes, particularly for patients with BRCA2 alterations. These findings suggest potential cross-resistance and underscore the need for prospective studies assessing the optimal sequencing of these agents.

来源:Eur Urol Oncol,查看原文。版权归原作者所有。

引用

  1. Raychaudhuri R, Tuchayi AM, Low SK, et al. Association of Prior PARP Inhibitor Exposure with Clinical Outcomes after 177Lu-PSMA-617 in Men with Castration-resistant Prostate Cancer and Mutations in DNA Homologous Recombination Repair Genes. Eur Urol Oncol. 2025. PMID: 39920014. doi:10.1016/j.euo.2025.01.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。